Topical immunotherapy with diphenylcyclopropenone in vitiligo: A preliminary experience

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 6, 2008, Pages 628-631

  Aghaei, Shahin ^a   Ardekani, Gholamreza ^a,b  

^a JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diphenylcyclopropenone; Immunotherapy; Treatment; Vitiligo

Indexed keywords

DIPHENCYPRONE; HYDROXYZINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEPIGMENTATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; FOCAL VITILIGO; HUMAN; IMMUNOTHERAPY; LOTION; MALE; MEDICAL PHOTOGRAPHY; PRURITUS; SCHOOL CHILD; SEGMENTAL VITILIGO; SKIN IRRITATION; SKIN PIGMENTATION; SKIN SENSITIZATION; SUN EXPOSURE; TREATMENT DURATION; VITILIGO; VITILIGO VULGARIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PILOT PROJECTS; VITILIGO; YOUNG ADULT;

EID: 59149091948     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.45108     Document Type: Article

References (17)

1. Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): Experience in an Iranian population. BMC Dermatol 2005;5:6.
2. Aghaei S. Treatment of disseminated facial warts through contact immunotherapy with diphenylcyclopropenone (DPCP). Dermatol Online J 2006;12:10.
3. Mahmoud F, Abul M, Hairies D, Al-Saleh C, Khajeji M, Whaley K. Decreased total numbers of peripheral blood lymphocytes with elevated percentage of CD4+CD45RO+ and CD4+CD25+ of T helper cells in non-segmental vitiligo. J Dermatol 2002;29:68-73.
4. Grimes P, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L. T-cell profiles in vitiligo. J Am Acad Dermatol 1986;14:196-9.
5. Halder RM, Walters CS, Johnson BA, Chakrabarti SG, Kenney JA Jr. Aberration of T-lymphocytes and natural killer cell in vitiligo. J Am Acad Dermatol 1986;14:733-7.
6. Le Poole IC, Wankowicz-Kalinska A, Van den Wijingaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004;9:68-72.
7. Erf GF, Trejo-Steal I, Smyth JR. T-cells in regenerating feather of Smyth line chicken with vitiligo. Clin Immunol Immunopathol 1995;76:120-6.
8. Grimes PE. Psoralen photochemotherapy in patients with vitiligo. Clin Dermatol 1997;15:921-6.
9. Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: A 10-year retrospective study. Clin Exp Dermatol 2002;27:104-10.
10. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: Metaanalysis of the literature. Arch Dermatol 1998;134:1532-40.
11. Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci 2000;23:S17-21.
12. Whittaker M. Severe dermatitis caused by diphenylcyclopropenone. Contact Dermatitis News Lett 1972;11:264.
13. Wilkerson MG, Henkin J, Wilkin JK. Diphenylcyclopropenone: Examination of potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol.1984;11:802-7.
14. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980;267:109-14.
15. Duhra P, Foulds IS. Persistent vitiligo induced by diphencyprone. Br J Dermatol 1990;123:415-6.
16. Hatzis J, Gourgiotou K, Tosca A, Varelzidis A, Stratigos J. Vitiligo as a reaction to topical treatment with diphencyprone. Dermatologica 1988;177:146-8.
17. Orecchia G, Perfetti L. Vitiligo and topical allergens. Dermatologica 1989;179:137-8.